San Antonio, TXNCT06811324Now EnrollingIRB Ready

Obesity Prevention Clinical Trial in San Antonio, TX

Access cutting-edge obesity prevention treatment through this clinical trial at a research site in San Antonio. Study-provided care at no cost to qualified participants.

Sponsored by The University of Texas Health Science Center at San Antonio

Quick Self-Assessment

See if you qualify for this San Antonio location

Preparing your pre-screening questions…

Expert Care in San Antonio

Access obesity prevention specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related obesity prevention treatment provided free

Apply for This San Antonio Location

Check if you qualify for this obesity prevention clinical trial in San Antonio, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Antonio

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Antonio site if eligible
  4. 4Begin participation

About This Obesity Prevention Study in San Antonio

Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.

Sponsor: The University of Texas Health Science Center at San Antonio

Who Can Participate

Inclusion Criteria

Men and postmenopausal women aged 50 years or older.
Body Mass Index (BMI) ≥30 kg/m².
Untreated HbA1c \<6.5% at baseline.
Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.
Able to provide informed consent and participate in all study assessments.

Exclusion Criteria

Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c ≥ 6.5%.
Body Mass Index (BMI) ≥ 40 kg/m².
Moderate to severe gastroesophageal reflux disease based on patient history.
Inability to comply with the treatment protocol or to understand the consent form.
Chronic Kidney Disease (CKD) Stage 4.
Aspartate aminotransferase (AST) \> 33 U/L or alanine aminotransferase (ALT) \> 36 U/L.
Active pregnancy.
Personal or family history of medullary thyroid carcinoma.
Personal or family history of multiple endocrine neoplasia type 2 syndrome.
Personal history of gastroparesis.
Personal history of diabetic retinopathy.
Known serious hypersensitivity, including anaphylaxis and angioedema, to Tirzepatide or any of its excipients.
Known serious hypersensitivity, including anaphylaxis and angioedema, to any GLP-1 receptor agonist class of therapies.
Concomitant treatment with GLP-1 receptor agonist therapy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Antonio?

Yes, this clinical trial (NCT06811324) has an active research site in San Antonio, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Obesity Prevention Treatment Options in San Antonio, TX

If you're searching for obesity prevention treatment options in San Antonio, TX, this clinical trial (NCT06811324) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Antonio research site is actively enrolling participants for this clinical trial. You'll receive care from experienced obesity prevention specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all obesity prevention clinical trials near you to find additional studies recruiting in your area.

More Obesity Trials in San Antonio, TX

See all obesity clinical trials recruiting in San Antonio — not just this study.

Browse Obesity Trials in San Antonio

Browse More Trials by Condition

Ready to Join in San Antonio?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Antonio, TX